Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer
Year: 2026
Type: article
Abstract: Estrogen receptor α (ERα) remains the principal molecular driver of hormone-dependent breast cancer. In this study, we designed, synthesized, and biologically evaluated a new series of secosteroid–isatin hybrids as potential ERα-targeting anticancer agents. The lead compounds, (Z)-3a and (Z)-3b, inhibited MCF-7 cell growth with IC50 values of 6.8 and 6.0 μM, respectively, comparable to cisplatin; they were approximately threefold less potent against epithelial cells than against the target cell model of ERα-positive breast cancer. Mechanistic studies demonstrated that both compounds induced a concentration-dependent depletion of ERα protein, accompanied by downregulation of the ERα-dependent proliferative mediator cyclin D1 and the anti-apoptotic protein Mcl-1, together with accumulation of cleaved PARP, indicating activation of apoptotic cell death. Importantly, an estrogen response element (ERE)-driven luciferase reporter assay demonstrated potent concentration-dependent suppression of 17β-estradiol-induced ERα transcriptional activity, with nearly complete inhibition achieved at higher concentrations, confirming that these compounds function as effective antagonists of ERα-dependent gene transcription. Furthermore, both lead compounds exhibited predominantly synergistic interactions with doxorubicin and heliomycin, suggesting their potential utility in combination therapy. Collectively, these findings identify secosteroid–isatin hybrids as a previously unexplored class of ERα modulators with efficient suppression of estrogen receptor α signaling and induction of apoptosis, which highlights this scaffold as a promising platform for the development of next-generation therapeutics for hormone-dependent breast cancer.
Source: Molecules
Authors: Alexey I. Ilovaisky, Alexander M. Scherbakov, Fedor B. Bogdanov, Valentina M. Merkulova, Elena I. Chernoburova, Andrey S. Dmitrenok, Diana I. Salnikova, Olga E. Andreeva, Danila V. Sorokin, Andrey E. Shchekotikhin, Eugene I. Bozhenko, Mikhail E. Minyaev, Quoc Long Pham, Do Huu Nghi, Dang Thu Quynh, Ivan A. Yaremenko, Igor V. Zavarzin, Alexander O. Terent’ev
Institutions: Russian Academy of Sciences, N.D. Zelinsky Institute of Organic Chemistry, Russian Cancer Research Center NN Blokhin, Gause Institute of New Antibiotics Russian Academy of Medical Sciences, Ton Duc Thang University, Viện Hóa học, Vietnam Academy of Science and Technology, Nam Can Tho University
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,258
Funder: Russian Science Foundation
Awards: G5809439742, G9001363677
OpenAlex ID: W7225872224
